1605.40
2.42%
Deven Choksey
We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 25% / 46.9% / 57.5% for the period of FY26-FY28E. The company is currently trading at 31x FY28E and we value the company at a PE of 33x FY28E EPS, implying a target price of INR 1,471 with the upside of 6.6%.
Tatva Chintan Pharma has gained 26.42% in the last 6 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended